PMID- 33049719
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230123
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 12
IP  - 19
DP  - 2020 Oct 13
TI  - Comparison of exosomes derived from induced pluripotent stem cells and 
      mesenchymal stem cells as therapeutic nanoparticles for treatment of corneal 
      epithelial defects.
PG  - 19546-19562
LID - 10.18632/aging.103904 [doi]
AB  - Induced pluripotent stem cells and mesenchymal stem cells are pluripotent stem 
      cells that represent promising therapies for treating various tissue injuries and 
      wound healing. Exosomes are nanosized extracellular vesicles that have been 
      identified as important mediators of therapeutic functions, which are performed 
      via cell communication. In this study, we compared the efficacy of induced 
      pluripotent stem cells-derived exosomes (iPSCs-Exos) and mesenchymal stem 
      cells-derived exosomes (MSCs-Exos) in treating corneal epithelial defects. The 
      characteristics of the two types of exosomes were not significantly different. 
      Compared to MSCs-Exos, iPSCs-Exos had a better in vitro effect on the 
      proliferation, migration, cell cycle promotion and apoptosis inhibition of human 
      corneal epithelial cells. iPSCs/MSCs-Exos promoted cell regeneration by 
      upregulating cyclin A and CDK2 to drive HCECs to enter the S phase from the G0/G1 
      phase. In vivo results from a corneal epithelial defect model showed that both 
      iPSCs-Exos and MSCs-Exos accelerated corneal epithelium defect healing while the 
      effects of iPSCs-Exos were much stronger than those of MSCs-Exos. This study 
      demonstrated that iPSCs-Exos had a better therapeutic effect on corneal 
      epithelial defect healing. Thus, a novel potential nanotherapeutic strategy for 
      treating corneal epithelial defects and even more ocular surface disease could be 
      undertaken by using iPSCs-Exos dissolved in eye drops.
FAU - Wang, Shudan
AU  - Wang S
AD  - Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, China.
FAU - Hou, Yunlong
AU  - Hou Y
AD  - College of Integrated Traditional Chinese and Western Medicine, Hebei University 
      of Chinese Medicine, Shijiazhuang 050200, China.
AD  - National Key Laboratory of Collateral Disease Research and Innovative Chinese 
      Medicine, Shijiazhuang 050200, China.
FAU - Li, Xuran
AU  - Li X
AD  - Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, China.
FAU - Song, Zhen
AU  - Song Z
AD  - Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, China.
FAU - Sun, Baoqi
AU  - Sun B
AD  - Department of Ophthalmology, Affiliated Hospital of Weifang Medical University, 
      Weifang 261042, China.
FAU - Li, Xinyue
AU  - Li X
AD  - Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, China.
LA  - eng
PT  - Journal Article
DEP - 20201013
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
SB  - IM
PMC - PMC7732275
OTO - NOTNLM
OT  - corneal epithelial defect
OT  - exosomes
OT  - induced pluripotent stem cells
OT  - mesenchymal stem cells
OT  - therapeutics
COIS- CONFLICTS OF INTEREST: The authors have declared that no conflicts of interest.
EDAT- 2020/10/14 06:00
MHDA- 2020/10/14 06:01
PMCR- 2020/10/15
CRDT- 2020/10/13 20:17
PHST- 2020/04/24 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2020/10/14 06:01 [medline]
PHST- 2020/10/13 20:17 [entrez]
PHST- 2020/10/15 00:00 [pmc-release]
AID - 103904 [pii]
AID - 10.18632/aging.103904 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2020 Oct 13;12(19):19546-19562. doi: 10.18632/aging.103904. 
      Epub 2020 Oct 13.